title: Children's Oncology Group's 2013 blueprint for research: stem cell transplantation.
abstract: The role of SCT in pediatric oncology has continued to evolve with the introduction of new therapeutic agents and immunological insights into cancer. COG has focused its efforts on the study of hematopoietic stem cell transplantation in the treatment of pediatric malignancies in several major multi-institutional Phase II and Phase III studies. These studies include addressing the impact of allogenicity in ALL (ASCT0431), and establishing autologous stem cell transplant as the standard of care in neuroblastoma. Reducing transplant-associated toxicity was addressed in the ASCT0521 study, where the TNFα inhibitor etanercept was tested for the treatment of idiopathic pneumonia syndrome. Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN-0501, in close collaboration with the BMT-CTN.
authors.affiliation: Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104-4318, USA. grupp@email.chop.edu
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Grupp
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Dvorak
authors.forename: Michael L
authors.initials: ML
authors.lastname: Nieder
authors.forename: John E
authors.initials: JE
authors.lastname: Levine
authors.forename: Donna A
authors.initials: DA
authors.lastname: Wall
authors.forename: Bryan
authors.initials: B
authors.lastname: Langholz
authors.forename: Michael A
authors.initials: MA
authors.lastname: Pulsipher
mesh_terms: D002648:Child; D002986:Clinical Trials as Topic; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000601:surgery*; D012106:Research